EuroBiotech: More Articles of Note

(NS Newsflash/CC BY 2.0)

> Symphogen moved antibodies against LAG3 and TIM3 into phase 1. The Danish biotech discovered the immuno-oncology prospects in the 2016 pact it formed with Shire. Statement 

> BioNTech named Özlem Türeci, M.D., as its CMO. Türeci founded and later led Ganymed Pharmaceuticals, which was bought by Astellas for €422 million ($494 million) upfront in 2016. Release   

> Treeway stepped up preparations for a phase 3 amyotrophic lateral sclerosis trial after bringing its asset through an early test of bioavailability and safety. The Dutch biotech is developing an oral formulation of Radicava. Statement 

> Bayer and Boehringer Ingelheim contributed to High-Tech Gründerfonds’ third fund. The pharma companies helped the German seed fund raise €316.5 million ($370 million) for its latest investment vehicle. Release

> Allergy Therapeutics posted clinical data on its house-dust mite immunotherapy. Statement  

> Evotec and Arix Bioscience entered into a strategic collaboration with Fred Hutchinson Cancer Research Center. The partners will create and support cancer and infectious disease startups. Release